AVLN (Avalyn Pharma) Revenue: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
12 GF Score
Price $31.85
View Full Analysis

What is Avalyn Pharma Revenue?

Avalyn Pharma AVLN -4.66% 12 Revenue is $0.00 Mil as of Jun. 2026. GuruFocus rates AVLN with a GF Score™ of 12/100.

Avalyn Pharma's revenue for the three months ended in Jun. 2026 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil. Avalyn Pharma's Revenue per Share for the three months ended in Jun. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Avalyn Pharma  (NAS:AVLN) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Avalyn Pharma Revenue Related Terms

Avalyn Pharma Revenue Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Revenue Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Revenue
0.00 0.00

Avalyn Pharma Quarterly Data
Mar25 Jun25 Mar26 Jun26
Revenue 0.00 0.00 0.00 0.00

AVLN vs LBRX, LTGO, NVAX: Revenue Comparison

For the Biotechnology subindustry, Avalyn Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalyn Pharma Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Revenue distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's Revenue falls into.


AVLN
12GF Score
Avalyn Pharma Inc AVLN
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
Avalyn Pharma (AVLN) has a Revenue of $0.00 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Avalyn Pharma and its competitors.
Is Avalyn Pharma's Revenue too high?
Avalyn Pharma's current Revenue is $0.00 Mil. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Revenue compare to LBRX and LTGO?
Avalyn Pharma's Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Revenue is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score

Get the complete analysis for AVLN

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.85
Price